Robert L. Coleman, MD, FACOG, FACS, discusses the results of the phase III VELIA trial in patients with advanced ovarian cancer.
Robert L. Coleman, MD, FACOG, FACS, professor, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses the results of the phase III VELIA trial in patients with advanced ovarian cancer.
Data from the phase III trial were presented at the 2019 ESMO Congress and demonstrated that the frontline combination of veliparib and chemotherapy followed by veliparib maintenance led to a significant improvement in progression-free survival (PFS) versus chemotherapy and placebo followed by placebo maintenance among patients with newly diagnosed, metastatic ovarian cancer.
The regimen was evaluated among the overall population, patients with germline and somaticBRCAmutations, and those with homologous recombination deficiency (HRD), says Coleman. Among patients with BRCA